The 2015 Treatment Guideline for Diabetes recommends statin therapy as the mainstay of management for dyslipidemia in order to lower low-density lipoprotein (LDL) cholesterol and thus prevent cardiovascular disease. It maintained the target LDL cholesterol level, in contrast to the 2013 American College of Cardiology/American Heart Association guideline, which did not recommend specific treatment targets as there is no well-established cardiovascular risk calculation model for the Korean population, and controversies exist regarding statin intensity. Therefore, further extensive research is needed to provide evidence for a specific treatment policy. The desirable levels of triglycerides and high-density lipoprotein cholesterol were suggested, but no specific drug treatment was recommended. Combination therapy with fibrate or niacin has been shown not to provide additional cardiovascular benefit above statin therapy alone and was not generally recommended. The addition of ezetimibe to statin therapy has been shown to provide additional cardiovascular benefit compared with statin therapy alone and so can be considered in patients with recent acute coronary syndrome.